Holen Sie sich die Stockscreener-App
8.67
0.46%
0.04
Vorhandelsmarkt:
8.59
-0.08
-0.92%
Schlusskurs vom Vortag:
$8.63
Offen:
$8.57
24-Stunden-Volumen:
45,404
Relative Volume:
0.50
Marktkapitalisierung:
$80.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.42M
KGV:
-1.5479
EPS:
-5.6013
Netto-Cashflow:
$-7.45M
1W Leistung:
+4.71%
1M Leistung:
+25.65%
6M Leistung:
+12.31%
1J Leistung:
+301.39%
1-Tages-Spanne:
$8.3012
$8.85
1-Wochen-Bereich:
$8.15
$9.22
52-Wochen-Spanne:
$1.80
$16.94
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Vergleichen Sie CRVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
8.67 | 79.85M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Yahoo Finance UK
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-12-06 11:12:10 - BỘ NỘI VỤ
CervoMed Inc Announces New Data from RewinD-LB Trial - TradingView
Today's Analyst Rating: CRVO Maintains "Buy" with $31 Price Targ - GuruFocus
Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Daily Volume Surge Signals - Newser
What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser
CervoMed’s DLB drug shows promise in phase 2b trial By Investing.com - Investing.com Nigeria
CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com
Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - The Manila Times
CervoMed stock soars after promising dementia drug trial results By Investing.com - Investing.com South Africa
CervoMed stock soars after promising dementia drug trial results - Investing.com
CervoMed Inc. Reports Phase 2b RewinD-LB Trial Results for Neflamapimod, Showing Significant Improvements in Dementia with Lewy Bodies Patients - Quiver Quantitative
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewswire Inc.
How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser
Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser
CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com Canada
CervoMed (CRVO) Maintains Buy Rating with Target Price of $31 | - GuruFocus
CervoMed (CRVO) Unveils Promising Phase 2b Trial Results for Alz - GuruFocus
Neflamapimod reduces key neurodegeneration markers in DLB study - Investing.com
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - marketscreener.com
How CervoMed Inc. (DP8) stock gains from tech spending2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - Newser
What analyst consensus says on CervoMed Inc. stockRecession Risk & Free Fast Gain Swing Trade Alerts - BỘ NỘI VỤ
CervoMed Inc. (CRVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - ADVFN
CervoMed Inc Stock Analysis and ForecastVolume Profile Analysis & Explosive Profit Growth - earlytimes.in
CervoMed Inc. to Present Phase 2b Trial Results of Neflamapimod for Dementia with Lewy Bodies at CTAD Conference - Quiver Quantitative
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia With Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - 富途牛牛
CervoMed Executives Make Bold Moves with Major Stock Purchases! - TipRanks
Will CervoMed Inc. stock outperform Nasdaq indexWeekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com
CervoMed Inc. Stock (CRVO) Opinions on Insider Buying and Clinical Trial Progress - Quiver Quantitative
CervoMed Inc. stock retracement – recovery analysisChart Signals & Smart Money Movement Tracker - newser.com
Will CervoMed Inc. (DP8) stock deliver compounding returns2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO - Investing.com Australia
CervoMed CEO Alam buys shares worth $182,736 By Investing.com - Investing.com Australia
Elder William buys CervoMed (CRVO) stock worth $29,250 By Investing.com - Investing.com Canada
Insider Buying: Matthew Winton Acquires Additional Shares of Cer - GuruFocus
Gregoire Sylvie buys CervoMed (CRVO) shares worth $182,736 By Investing.com - Investing.com Canada
CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO By Investing.com - Investing.com South Africa
Elder William buys CervoMed (CRVO) stock worth $29,250 - Investing.com
CervoMed CEO Alam buys shares worth $182,736 - Investing.com India
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):